Zobrazeno 1 - 10
of 16
pro vyhledávání: '"Nusayba A. Bagegni"'
Autor:
Andrew A. Davis, Lorenzo Gerratana, Katherine Clifton, Arielle J. Medford, Marko Velimirovic, Whitney L. Hensing, Leslie Bucheit, Ami N. Shah, Paolo D'Amico, Carolina Reduzzi, Qiang Zhang, Charles S. Dai, Elyssa N. Denault, Nusayba A. Bagegni, Mateusz Opyrchal, Foluso O. Ademuyiwa, Ron Bose, William J. Gradishar, Amir Behdad, Cynthia X. Ma, Aditya Bardia, Massimo Cristofanilli
Publikováno v:
EBioMedicine, Vol 86, Iss , Pp 104316- (2022)
Summary: Background: Limited data exist to characterise molecular differences in circulating tumour DNA (ctDNA) for patients with invasive lobular carcinoma (ILC). We analysed metastatic breast cancer patients with ctDNA testing to assess genomic dif
Externí odkaz:
https://doaj.org/article/07b125b3c92b42acba72a92a3f8e5d48
Autor:
Soumon Rudra, MD, Amit Roy, MD, Randall Brenneman, MD, Prashant Gabani, MD, Michael C. Roach, MD, Laura Ochoa, ANP, PhD, Heidi Prather, DO, Catherine Appleton, MD, Julie Margenthaler, MD, FACS, Lindsay L. Peterson, MD, MSCR, Nusayba A. Bagegni, MD, Jacqueline E. Zoberi, PhD, Jose Garcia-Ramirez, MS, Maria A. Thomas, MD, PhD, Imran Zoberi, MD
Publikováno v:
Advances in Radiation Oncology, Vol 6, Iss 1, Pp 100602- (2021)
Purpose: Our purpose was to describe the risk of radiation-induced brachial plexopathy (RIBP) in patients with breast cancer who received comprehensive adjuvant radiation therapy (RT). Methods and Materials: Records for 498 patients who received comp
Externí odkaz:
https://doaj.org/article/6fdef972425141e6a41a2118f4201984
Autor:
Mara Hofherr, Jennifer Hedgecorth, Foluso O. Ademuyiwa, Lindsay L. Peterson, Nusayba A. Bagegni, Rama Suresh, Ashley Frith, Ron Bose, Katherine Weilbaecher, Cynthia Ma, Andrew A. Davis, Katherine K. Clifton
Publikováno v:
Cancer Research. 83:P3-06
Background: KEYNOTE-522 was a randomized, double-blind, placebo-controlled phase 3 trial which resulted in the FDA approval of pembrolizumab with neoadjuvant chemotherapy for patients (pts) with newly diagnosed, high-risk, early-stage triple negative
Autor:
Nusayba A. Bagegni, Isabella Grigsby, Leslie Nehring, Jingqin Luo, Jennifer Powers Carson, David W. Gibson, Meghan Horvath, Katherine K. Clifton, Foluso O. Ademuyiwa, Rama Suresh, Ashley Frith, Andrew A. Davis, Lindsay L. Peterson, Ron Bose, Amy Williams, Mattias Bergqvist, Cynthia Ma
Publikováno v:
Cancer Research. 83:OT3-11
Background: CDK 4/6i have altered the therapeutic landscape of HR+, HER2- MBC, improving progression free and overall survival (PFS and OS) compared to endocrine therapy (ET) alone. Despite durable responses to CDK 4/6i in a large majority of patient
Autor:
Katherine K. Clifton, Shana N. Thomas, Jingqin Luo, Jing Xi, Nusayba A. Bagegni, Foluso O. Ademuyiwa, Rama Suresh, Ashley Frith, Andrew A. Davis, Ron Bose, Katherine Weilbaecher, Whitney L. Hensing, Timothy Pluard, Massimo Cristofanilli, Hyo S. Han, Adam M. Brufsky, Kevin Kalinsky, Shom Goel, Seth A. Wander, Lindsay L. Peterson, Cynthia Ma
Publikováno v:
Cancer Research. 83:PD13-09
Background: CDK4/6 inhibitors (CDK4/6i) paired with endocrine therapy (ET) are considered first-line (1L) therapy for patients (pts) with HR+ HER2- advanced breast cancer (aBC). A minority of pts will demonstrate primary resistance to CDK4/6i, as cha
Autor:
Andrew A. Davis, Leonel Hernandez-Aya, Jingqin Luo, Mateusz Opyrchal, Foluso O. Ademuyiwa, Nusayba A. Bagegni, Katherine K. Clifton, Jill Anderson, Trish Hammerschmidt, Leslie Nehring, David DeNardo, Mark Watson, Rebecca Aft, Cynthia Ma, Katherine Weilbaecher
Publikováno v:
Cancer Research. 83:P3-06
Background: Neoadjuvant immune checkpoint inhibition (ICI) in combination with chemotherapy is approved for patients with high-risk, early-stage triple-negative breast cancer (TNBC) based on improved outcomes in the KEYNOTE-522 trial. However, some p
Autor:
Whitney L. Hensing, Joanne Xiu, W. Michael Korn, Stephanie L. Graff, Irene Kang, Evanthia T. Roussos Torres, Arielle L. Heeke, Andrew A. Davis, Nusayba A. Bagegni, Katherine K. Clifton, Ron Bose, Cynthia Ma, Foluso O. Ademuyiwa
Publikováno v:
Cancer Research. 83:P3-05
Introduction: Estrogen receptor (ER) loss occurs in about 20% of recurrent breast cancers (BC) and is associated with unresponsiveness to endocrine therapy (ET) and poor prognosis. Prior studies evaluating ER-loss included predominately patients with
Publikováno v:
Breast Cancer: Targets and Therapy. 14:113-123
Triple-negative breast cancer (TNBC) is a biologically aggressive yet heterogeneous disease that disproportionately affects younger women and women of color compared to other breast cancer subtypes. The paucity of effective targeted therapies and the
Autor:
Nusayba A. Bagegni, Haeseong Park, Katlyn Kraft, Maura O-Toole, Feng Gao, Saiama N. Waqar, Lee Ratner, Daniel Morgensztern, Siddhartha Devarakonda, Manik Amin, Maria Q. Baggstrom, Chris Liang, Giovanni Selvaggi, Andrea Wang-Gillam
Publikováno v:
Cancer chemotherapy and pharmacology. 89(4)
Purpose Vorolanib is a multi-target tyrosine kinase inhibitor with anti-angiogenic properties. This study aimed to evaluate the tolerability, safety and efficacy of vorolanib when added to checkpoint inhibitors (CPIs) in patients with advanced solid
Autor:
Nusayba Ali Bagegni, Leslie Nehring, Jill Anderson, Brittney Haas, Jingqin Luo, Meghna S. Trivedi, Laura Carpin Kennedy, Manali A. Bhave, Karen Colleen Daily, Wajeeha Razaq, Yiling Lu, Wei-Lien Wang, Gerburg M. Wulf, Rabih Said, Cynthia X. Ma
Publikováno v:
Journal of Clinical Oncology. 40:TPS1128-TPS1128
TPS1128 Background: Metastatic (met) TNBC remains a clinical challenge with limited treatment options and inevitable chemoresistance. Aberrant PI3K pathway signaling is frequently observed in TNBC. Increasing evidence shows PI3K pathway activation ma